Atea Pharmaceuticals Inc
AVIR
Get informed when a big investor buys or sells
+ FollowMarket Cap$426.54M
Close$
$1.16
78% downside
Current Fair Value
78% downsideOvervalued by 78% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $426.54 Million |
|---|---|
| Enterprise Value | $350.42 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.94 |
| Beta | 0.29 |
| Outstanding Shares | 80,050,518 |
Return
| Return on Equity | -80.96% |
|---|---|
| Return on Assets | -71.16% |
| Return on Invested Capital | -88.86% |
Valuation & Multiples
| P/E Ratio | -2.56 |
|---|---|
| PEG | 22.52 |
| Price to Sales | - |
| Price to Book Ratio | 2.64 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.93 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
$33.03 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.55
Average shareholder expectationRevenue Estimate
$50.45 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 11,200▼ 88.70% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 75.88%▼ 0.00% |
|---|---|
| Total Invested | $279.92M▼ 13.27% |
| Investors Holding | 127▼ 2.00% |
ESG Score
No data
About Atea Pharmaceuticals Inc
39 employeesAtea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of...